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Clinical manifestations of D. jamesoni toxins
Early clinical signs
• Paralysis
• Fasciculation
• Vertigo
• Ataxia
• Sudden loss of consciousness
Late clinical signs
• Shock
• Hypotension
• Abdominal pain
• Epistaxis
• Pallor
• Increased sweating
• Nausea
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Local tissue damage appears to be relatively infrequent and of minor
severity in most cases, whereas the accumulative effect of symptoms
may lead to death if not treated4.
Toxicovenomics
Selection of scFvs by phage display
Format conversion of scFv to IgG
Production of recombinant antibody mixtures
Perspectives
This project aims to develop a fully recombinant snakebite
antivenom against the potent venom of D. jamesoni. This antivenom
will be based on selected human IgG antibodies, compatible with
the human immune system and with proven specificity. It is the
ambition of this project to contribute to the development of safer,
more effective, and inexpensive treatment options against snakebite
envenoming.
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The pressing problem of a snakebite
Each year, more than 5 million people worldwide are affected by a
snakebite, resulting in 150,000 deaths, and 400,000 amputations1.
The current medical treatment against envenoming is based on the
administration of an animal-derived antiserum, containing
antibodies against snake venom toxins. Due to the heterologous and
immunogenic nature of antivenom, patients in up to 80% of the
cases experience serum sickness and anaphylaxis, which in some
cases leads to death2, 3.
